Salarius Pharmaceuticals, Inc.

Clinical-stage biopharma developing targeted protein therapies for cancer and viral diseases.

SLRX | NDAQ

Overview

Corporate Details

ISIN(s):: N/A
LEI:
Country:: United States of America
Address:: 2450 HOLCOMBE BLVD, 77021 HOUSTON
Website:: https://salariuspharma.com/
Sector:: Mining and quarrying
Industry:: Mining of non-ferrous metal ores

Description

Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for patients with cancer and other diseases with high unmet medical needs. The company's technology aims to correct the dysregulated gene expression that drives disease progression. Its pipeline is built on two primary drug classes: targeted protein inhibitors (TPIs) and targeted protein degraders (TPDs). The lead TPI candidate, seclidemstat (SP-2577), is in Phase 1/2 clinical trials for solid and hematologic cancers like leukemias and lymphomas. The company's TPD candidate, SP-3164, is in IND-enabling studies. Following a merger with Decoy Therapeutics, Salarius is also advancing peptide therapeutics for cancer and respiratory viruses.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Salarius Pharmaceuticals, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Salarius Pharmaceuticals, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Salarius Pharmaceuticals, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
CARTA HOLDINGS, INC. Digital marketing firm offering ad platforms and integrated solutions to empower businesses.	Japan	3688
Celyad Oncology SA Clinical-stage biotech developing CAR T therapies for solid and blood cancers.	Belgium	CYAD
CENTAUR MEDIA PLC Provides business intelligence, learning, and consultancy for marketing & legal professionals.	United Kingdom	CAU
Century Therapeutics, Inc. Developing iPSC-derived, off-the-shelf cell therapies for cancer & autoimmune diseases.	United States of America	IPSC
Cereno Scientific AB Develops epigenetic therapies for rare cardiovascular and pulmonary diseases.	Sweden	CRNO
CERES INC. Develops online media platforms connecting consumers with advertisers through a rewards system.	Japan	3696
Certara, Inc. Accelerating new medicines with biosimulation software and services for pharma & biotech.	United States of America	CERT
CEVA INC Licensor of DSP, AI, wireless, and sensing IP for low-power, smart edge devices.	United States of America	CEVA
Chabiotech Co.,Ltd. Develops cell/gene therapies and offers CDMO, biobanking, and genomics services for rare diseases.	South Korea	085660
Chai Communication Co., LTD. An Ad-Tech firm providing digital marketing, SEO, social media, and creative ad solutions.	South Korea	351870